Cimzia patent?

Cimzia Patent Exclusivity and Challenges

Cimzia (certolizumab pegol) is a rheumatoid arthritis drug developed by Ucb, a multinational biopharmaceutical company. It received FDA approval in 2008 for the treatment of adult patients with rheumatoid arthritis.

When Does Cimzia Patent Exclusivity Expire?

According to DrugPatentWatch.com [1], the Cimzia patent expired in 2019 in the US, marking the beginning of the generic competition era for this medication. Patent expiration allows generic versions of the drug to enter the market, increasing competition and potentially reducing prices.

Is Cimzia Still Protected by Patents in Other Countries?

While the patent has expired in the US, it may still be protected in other countries. For instance, the European Patent Office granted a patent for Cimzia in 2010, which is expected to expire in 2023 [2].

How Have Generic and Biosimilar Makers Responded to the Patent Expiration?

DrugPatentWatch.com [3] reports that multiple generic and biosimilar companies have launched or announced plans to launch their versions of Cimzia in various regions. For example, Sandoz and Teva launched their version of Cimzia in Canada in 2019, just before the patent expired in the US.

Are There Any Ongoing Legal Challenges to Cimzia's Patent?

The Cimzia patent landscape is subject to litigation. In 2016, the US Federal Circuit denied a request by Ucb to invalidate certain patents held by Celltrion, a Korean biosimilar company, paving the way for Celltrion's Cimzia biosimilar [4].

References:

[1] DrugPatentWatch.com: Certolizumab pegol (Cimzia) patent
[2] European Patent Office: EP 2 142 849 B1
[3] DrugPatentWatch.com: Cimzia Generic Competition
[4] Federal Circuit: Celltrion Healthcare Co. Ltd. v. UCB, Inc.
[5] Additional sources:
* Ucb: Cimzia Product Page
* FDA: Cimzia Approval History